Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tarsus Pharmaceuticals, Inc. (TARS : NSDQ)

• Company Description    Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif. Number of Employees: 323

• Price / Volume Information    Yesterday's Closing Price: $39.99 Daily Weekly Monthly 20 Day Moving Average: 614,847 shares Shares Outstanding: 42.01 (millions) Market Capitalization: $1,680.15 (millions) Beta: 0.80 52 Week High: $57.28 52 Week Low: $20.08 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.93% -12.27% 12 Week -10.40% -27.97% Year To Date -27.78% -31.46%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 15440 LAGUNA CANYON ROAD SUITE 160 - IRVINE,CA 92618 USA ph: 949-418-1801 fax: - dnakasone@tarsusrx.com http://www.tarsusrx.com

• General Corporate Information    Officers Bobak Azamian - President; Chief Executive Officer and Chairman Jeffrey Farrow - Chief Financial Officer and Chief Strategy Officer Scott Morrison - Director Bhaskar Chaudhuri - Director Andrew Goldberg - Director Peer Information Tarsus Pharmaceuticals, Inc. (CORR.) Tarsus Pharmaceuticals, Inc. (RSPI) Tarsus Pharmaceuticals, Inc. (CGXP) Tarsus Pharmaceuticals, Inc. (BGEN) Tarsus Pharmaceuticals, Inc. (GTBP) Tarsus Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87650L103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 42.01 Most Recent Split Date: (:1) Beta: 0.80 Market Capitalization: $1,680.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.31 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.23 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 50.76% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.91 Price/Cash Flow: - Price / Sales: 7.19 EPS Growth vs. Year Ago Period: 36.63% vs. Previous Quarter: -6.67% Sales Growth vs. Year Ago Period: 183.68% vs. Previous Quarter: 17.96% ROE 06/30/25 - - 03/31/25 - -39.72 12/31/24 - -46.71 ROA 06/30/25 - - 03/31/25 - -25.74 12/31/24 - -31.24 Current Ratio 06/30/25 - - 03/31/25 - 5.57 12/31/24 - 4.43 Quick Ratio 06/30/25 - - 03/31/25 - 5.54 12/31/24 - 4.39 Operating Margin 06/30/25 - - 03/31/25 - -44.91 12/31/24 - -63.16 Net Margin 06/30/25 - - 03/31/25 - -44.91 12/31/24 - -63.16 Pre-Tax Margin 06/30/25 - - 03/31/25 - -44.91 12/31/24 - -63.16 Book Value 06/30/25 - - 03/31/25 - 8.15 12/31/24 - 5.87 Inventory Turnover 06/30/25 - - 03/31/25 - 6.32 12/31/24 - 4.39 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.21 12/31/24 - 0.32 Debt-to-Capital 06/30/25 - - 03/31/25 - 17.37 12/31/24 - 24.24

Powered by Zacks Investment Research ©